Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...

AstraZeneca (NASDAQ:AZN) announced on Wednesday that its experimental breast cancer treatment, camizestrant, helped extend survival without disease progression in patients with an advanced form of the ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...

AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and ...

AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...